All In Biotech

Drug Trial Radar · NCT04294862

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

An Open-Label Study to Evaluate Tissue Distribution, Plasma Pharmacokinetics, Safety, and Tolerability After a Single Intravenous Dose of TNP-2092 in Adult Participants Undergoing Primary Total Hip or Knee Arthroplasty

Last checked: Nov 20, 2026Latest source record: Oct 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Mar 1, 2021

Primary completion

Dec 31, 2021

Study completion Jun 29, 2022

Sponsor

Lead sponsor
TenNor Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Mar 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA). Tissue distribution is the primary objective, and plasma pharmacokinetics (PK), safety, and tolerability are secondary objectives.

Conditions

  • Prosthetic Joint Infection

Interventions

  • TNP-2092Drug

    TNP-2092 for injection 100mg/vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of TNP-2092 in synovial fluidTime frame: 2 hours after infusion
  2. Concentration of TNP-2092 in boneTime frame: 2 hours after infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rothman Orthopedic Institute

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.